CCL2 and neuroblastoma: While this study supports the addition of anti-CCL2 antibody to etoposide in the treatment of metastatic neuroblastoma due to its survival benefit, the discrepancy between the clear survival benefit and the lack of sustained suppression of metastatic disease burden warrants further investigation and highlights the limitations of this experimental model.